HK1108882A1 - Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists - Google Patents

Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists

Info

Publication number
HK1108882A1
HK1108882A1 HK07113993.3A HK07113993A HK1108882A1 HK 1108882 A1 HK1108882 A1 HK 1108882A1 HK 07113993 A HK07113993 A HK 07113993A HK 1108882 A1 HK1108882 A1 HK 1108882A1
Authority
HK
Hong Kong
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
pyrazolo
Prior art date
Application number
HK07113993.3A
Other languages
English (en)
Inventor
Martin C Clasby
Samuel Chackalamannil
Bernard R Neustadt
Xiaobang Gao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1108882A1 publication Critical patent/HK1108882A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK07113993.3A 2004-12-21 2007-12-20 Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists HK1108882A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63802804P 2004-12-21 2004-12-21
PCT/US2005/045658 WO2006068954A2 (en) 2004-12-21 2005-12-19 PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
HK1108882A1 true HK1108882A1 (en) 2008-05-23

Family

ID=36602229

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07113993.3A HK1108882A1 (en) 2004-12-21 2007-12-20 Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists

Country Status (11)

Country Link
US (1) US7741318B2 (xx)
EP (1) EP1836205B1 (xx)
JP (1) JP2008524330A (xx)
CN (1) CN101119998A (xx)
AT (1) ATE433454T1 (xx)
CA (1) CA2591125A1 (xx)
DE (1) DE602005014891D1 (xx)
ES (1) ES2327145T3 (xx)
HK (1) HK1108882A1 (xx)
MX (1) MX2007007604A (xx)
WO (1) WO2006068954A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2008027220A2 (en) * 2006-08-28 2008-03-06 Schering Corporation Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3, 3a-dihydropyrazol0 [1, 5-a] pyrimidin-7-yl) -amino derivatives
AU2009233963B2 (en) * 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
CN101906105B (zh) * 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
EP2501706B1 (en) 2009-11-18 2014-08-06 Council of Scientific & Industrial Research A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof
CN102770435B (zh) * 2010-02-26 2015-11-25 田边三菱制药株式会社 吡唑并嘧啶类化合物及其作为pde10抑制剂的用途
PT2576541T (pt) * 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US20140288052A1 (en) * 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
CN103626776B (zh) * 2013-12-05 2017-02-15 北京师范大学 吡唑并[1,5‑a]嘧啶氮芥衍生物及其制备方法和肿瘤治疗应用
US10913744B2 (en) * 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物、組成物、および方法
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CN112921405B (zh) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 一种合成On-DNA吡唑并[1，5-a]嘧啶化合物的方法
TW202245774A (zh) * 2021-02-05 2022-12-01 大陸商上海齊魯製藥研究中心有限公司 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
WO1998042711A1 (fr) 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
CZ20021089A3 (cs) * 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
AR041133A1 (es) * 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de la quinasa dependientes de la ciclina
JP4564485B2 (ja) * 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1618108A2 (en) 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2006068954A2 (en) 2006-06-29
WO2006068954A3 (en) 2006-12-07
JP2008524330A (ja) 2008-07-10
MX2007007604A (es) 2007-08-02
EP1836205A2 (en) 2007-09-26
EP1836205B1 (en) 2009-06-10
US7741318B2 (en) 2010-06-22
DE602005014891D1 (de) 2009-07-23
ATE433454T1 (de) 2009-06-15
ES2327145T3 (es) 2009-10-26
CN101119998A (zh) 2008-02-06
US20060135526A1 (en) 2006-06-22
CA2591125A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
HK1108882A1 (en) Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
NO20054085L (no) Substituerte heksahydropyrazino [1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
MXPA04003474A (es) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MXPA04003795A (es) Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
BR0116323A (pt) Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
HUP0400266A2 (hu) Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
TW200602058A (en) Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
DE60314623D1 (de) Substituierte pyrazolopyrimidine
YU41299A (sh) Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MX2007004250A (es) Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE242246T1 (de) (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
NZ512981A (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MXPA05010651A (es) Compuestos de pirazol.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131219